Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT
- Development stage
- Phase 2
- Lead developer
- Changhua Christian Hospital
- Administration
- Oral
01
Overview
**WT** is an orally administered concentrated traditional Chinese medicine powder under clinical evaluation by Changhua Christian Hospital for **spinocerebellar ataxia type 3**. Its composition and individual bioactive constituent were not publicly specified in the registered trial. The trial rationale states that WT contains a principal bioactive constituent reported preclinically to protect against glutamate-induced neurotoxicity, promote neurogenesis, and increase insulin-like growth factor 1 protein expression in ischemic rat brain. WT was studied in a randomized, double-blind, placebo-controlled crossover Phase 2 pilot trial using 3 g twice daily for 12 weeks per treatment period.
- Other names
- Chinese medicine WT
Beyond the preview
Go deeper on WT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT.